Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568888 · ClinicalTrials.gov registry record · Phase 3
Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )
A Phase 3 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,366
- Enrollment target
NCT05568888: Clinical Trial Phase 3 study, sponsored by CSL Behring.
NCT05568888 is a Phase 3 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 1,366 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05568888, a Phase 3 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,366 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Primary Outcome
Here, the percentage of participants with all-cause mortality has been reported. Percentages were rounded off if the second digit after the decimal point is equal to or more than five.
Interventions
- DRUG Placebo
- DRUG BE1116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,366 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 3 |
Why NCT05568888 stopped before completion
NCT05568888 is an interventional study that assigns participants to a tested intervention. Its 1,366 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05568888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05568888 about?
NCT05568888 is a clinical study titled "Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )". This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or...
What is the current status of trial NCT05568888?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,366 participants. The study started on 2023-03-28. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT05568888?
The interventions under investigation include: Placebo (DRUG), BE1116 (DRUG).
Who is sponsoring clinical trial NCT05568888?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05568888's enrollment target sits among peer trials
1,366 180th of 2000 higher than 1,821 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04489238 · 1,366 participants
Collection of Information to Better Understand Young Onset Colorectal Cancer
- NCT02677064 · 1,365 participants
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI